menu
    • menu
    [{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Neurology","graph2":"Phase I","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OliPass \/ Not Applicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Novotech"},{"orgOrder":0,"company":"OliPass","sponsor":"Vanda Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Antisense Oligonucleotide","moa":"mRNA","graph1":"Technology","graph2":"Preclinical","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"OliPass \/ OliPass","highestDevelopmentStatusID":"4","companyTruncated":"OliPass \/ OliPass"},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Not Applicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by OliPass

    Menu

    OliPass

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Sel...

                            Details : OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthrit...

                            Brand Name : OLP-1002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 13, 2023

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim F...

                            Details : OLP-1002 is an SCN9A antisense PNA and selectively inhibits the expression of Nav1.7 sodium channel in neuronal cells. It replicates much of the phenotype of people with a null mutation in the SCN9A gene. It is being investigated for chronic osteoarthrit...

                            Brand Name : OLP-1002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 16, 2023

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Technology

                            Study Phase : Preclinical

                            Recipient : Vanda Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeu...

                            Details : The collaboration will focus on editing and modifying gene expression using ASOs in disease states where the expression of genes is either altered or the sequence of the expressed genes can be altered for therapeutic benefit.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 29, 2022

                            Lead Product(s) : Antisense Oligonucleotide

                            Therapeutic Area : Technology

                            Highest Development Status : Preclinical

                            Recipient : Vanda Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Novotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002

                            Details : OLP-1002 is an SCN9A antisense peptide nucleic acid (PNA) and selectively inhibits the expression of Nav1.7 sodium channel, and therefore expected to replicate much of the phenotype of people with SCN9A channelopathy.

                            Brand Name : OLP-1002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 18, 2022

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Novotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed

                            OliPass

                            South Korea arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage

                            Details : OLP-1002 manifested excellent safety in a UK Phase 1 study evaluated in a total of 116 healthy volunteers. In the meantime, an exploratory Phase 1b study in Australia suggested clues to strong efficacy and long therapeutic duration in OA patients.

                            Brand Name : OLP-1002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 25, 2021

                            Lead Product(s) : OLP-1002

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth